Acceptability of home use of mifepristone for medical abortion

Yael Swica, Erica Chong, Tamer Middleton, Linda Prine, Marji Gold, Courtney A. Schreiber, Beverly Winikoff

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Most medical abortion protocols require women to take mifepristone in the doctor's office. We assessed the acceptability of home use of mifepristone among women and their providers. Study Design: In this multicenter trial, eligible women requesting termination of early pregnancy (n= 301) chose whether to take mifepristone in the office or at home. Data on safety, efficacy, acceptability and disability were collected. Results: One hundred thirty-nine women (46%) chose to take mifepristone at home, and 162 (54%) chose office administration. Ninety-five percent of home users said that they would take the mifepristone in the same place in the future. Home users were not more likely to call the doctor's office or make an unplanned visit, and providers would recommend home use again for 95% of patients who chose home use. Conclusions: Home administration of mifepristone was safe and acceptable to women and providers in our study. Women should be offered this choice to allow more flexibility, comfort and privacy in their abortion experiences.

Original languageEnglish (US)
Pages (from-to)122-127
Number of pages6
JournalContraception
Volume88
Issue number1
DOIs
StatePublished - Jul 2013

Fingerprint

Mifepristone
Privacy
Multicenter Studies
Safety
Pregnancy

Keywords

  • Home use
  • Medical abortion
  • Mifepristone

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Swica, Y., Chong, E., Middleton, T., Prine, L., Gold, M., Schreiber, C. A., & Winikoff, B. (2013). Acceptability of home use of mifepristone for medical abortion. Contraception, 88(1), 122-127. https://doi.org/10.1016/j.contraception.2012.10.021

Acceptability of home use of mifepristone for medical abortion. / Swica, Yael; Chong, Erica; Middleton, Tamer; Prine, Linda; Gold, Marji; Schreiber, Courtney A.; Winikoff, Beverly.

In: Contraception, Vol. 88, No. 1, 07.2013, p. 122-127.

Research output: Contribution to journalArticle

Swica, Y, Chong, E, Middleton, T, Prine, L, Gold, M, Schreiber, CA & Winikoff, B 2013, 'Acceptability of home use of mifepristone for medical abortion', Contraception, vol. 88, no. 1, pp. 122-127. https://doi.org/10.1016/j.contraception.2012.10.021
Swica, Yael ; Chong, Erica ; Middleton, Tamer ; Prine, Linda ; Gold, Marji ; Schreiber, Courtney A. ; Winikoff, Beverly. / Acceptability of home use of mifepristone for medical abortion. In: Contraception. 2013 ; Vol. 88, No. 1. pp. 122-127.
@article{b6fcdd7634024c04b5accf402d5b76c3,
title = "Acceptability of home use of mifepristone for medical abortion",
abstract = "Background: Most medical abortion protocols require women to take mifepristone in the doctor's office. We assessed the acceptability of home use of mifepristone among women and their providers. Study Design: In this multicenter trial, eligible women requesting termination of early pregnancy (n= 301) chose whether to take mifepristone in the office or at home. Data on safety, efficacy, acceptability and disability were collected. Results: One hundred thirty-nine women (46{\%}) chose to take mifepristone at home, and 162 (54{\%}) chose office administration. Ninety-five percent of home users said that they would take the mifepristone in the same place in the future. Home users were not more likely to call the doctor's office or make an unplanned visit, and providers would recommend home use again for 95{\%} of patients who chose home use. Conclusions: Home administration of mifepristone was safe and acceptable to women and providers in our study. Women should be offered this choice to allow more flexibility, comfort and privacy in their abortion experiences.",
keywords = "Home use, Medical abortion, Mifepristone",
author = "Yael Swica and Erica Chong and Tamer Middleton and Linda Prine and Marji Gold and Schreiber, {Courtney A.} and Beverly Winikoff",
year = "2013",
month = "7",
doi = "10.1016/j.contraception.2012.10.021",
language = "English (US)",
volume = "88",
pages = "122--127",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Acceptability of home use of mifepristone for medical abortion

AU - Swica, Yael

AU - Chong, Erica

AU - Middleton, Tamer

AU - Prine, Linda

AU - Gold, Marji

AU - Schreiber, Courtney A.

AU - Winikoff, Beverly

PY - 2013/7

Y1 - 2013/7

N2 - Background: Most medical abortion protocols require women to take mifepristone in the doctor's office. We assessed the acceptability of home use of mifepristone among women and their providers. Study Design: In this multicenter trial, eligible women requesting termination of early pregnancy (n= 301) chose whether to take mifepristone in the office or at home. Data on safety, efficacy, acceptability and disability were collected. Results: One hundred thirty-nine women (46%) chose to take mifepristone at home, and 162 (54%) chose office administration. Ninety-five percent of home users said that they would take the mifepristone in the same place in the future. Home users were not more likely to call the doctor's office or make an unplanned visit, and providers would recommend home use again for 95% of patients who chose home use. Conclusions: Home administration of mifepristone was safe and acceptable to women and providers in our study. Women should be offered this choice to allow more flexibility, comfort and privacy in their abortion experiences.

AB - Background: Most medical abortion protocols require women to take mifepristone in the doctor's office. We assessed the acceptability of home use of mifepristone among women and their providers. Study Design: In this multicenter trial, eligible women requesting termination of early pregnancy (n= 301) chose whether to take mifepristone in the office or at home. Data on safety, efficacy, acceptability and disability were collected. Results: One hundred thirty-nine women (46%) chose to take mifepristone at home, and 162 (54%) chose office administration. Ninety-five percent of home users said that they would take the mifepristone in the same place in the future. Home users were not more likely to call the doctor's office or make an unplanned visit, and providers would recommend home use again for 95% of patients who chose home use. Conclusions: Home administration of mifepristone was safe and acceptable to women and providers in our study. Women should be offered this choice to allow more flexibility, comfort and privacy in their abortion experiences.

KW - Home use

KW - Medical abortion

KW - Mifepristone

UR - http://www.scopus.com/inward/record.url?scp=84879084611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879084611&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2012.10.021

DO - 10.1016/j.contraception.2012.10.021

M3 - Article

VL - 88

SP - 122

EP - 127

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 1

ER -